KW
Kwangdong Healthbio Co., Ltd.
086220 | KO
Overview
Corporate Details
- ISIN(s):
- KR7086220001
- LEI:
- Country:
- South Korea
- Address:
- 충청북도 청원군 오창읍 양청송대길 39(송대리), 오창읍
- Website:
- http://www.kd-healthbio.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-06-04 00:00 |
Report Publication Announcement
기업설명회(IR)개최결과
|
Korean | 6.7 KB | ||
| 2025-05-21 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 7.1 KB | ||
| 2025-03-25 00:00 |
AGM Information
정기주주총회결과
|
Korean | 15.2 KB | ||
| 2025-03-17 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 9.6 KB | ||
| 2025-03-17 00:00 |
Annual / Quarterly Financial Statement
사업보고서 (2024.12)
|
Korean | 436.1 KB | ||
| 2025-03-10 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 114.1 KB | ||
| 2025-02-25 00:00 |
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
|
Korean | 26.1 KB | ||
| 2025-02-25 00:00 |
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
|
Korean | 25.1 KB | ||
| 2025-02-25 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 8.4 KB | ||
| 2025-02-25 00:00 |
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
|
Korean | 28.6 KB | ||
| 2024-12-11 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 4.4 KB | ||
| 2024-10-30 00:00 |
Report Publication Announcement
기업설명회(IR)개최결과
|
Korean | 6.7 KB | ||
| 2024-10-14 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 7.0 KB | ||
| 2024-08-20 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 53.3 KB | ||
| 2024-08-19 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
|
Korean | 53.6 KB |
Automate Your Workflow. Get a real-time feed of all Kwangdong Healthbio Co., Ltd. filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Kwangdong Healthbio Co., Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kwangdong Healthbio Co., Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.
United States of America
ANNX
United States of America
ANNX
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea
065660
South Korea
065660
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania
ATB
Romania
ATB
Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.
United States of America
APLS
United States of America
APLS
Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.
United States of America
APUS
United States of America
APUS
Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.
United States of America
APGE
United States of America
APGE
A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.
United States of America
APLM
United States of America
APLM
German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.
Germany
APPH
Germany
APPH
Develops treatments for rare metabolic and central nervous system (CNS) disorders.
United States of America
APLT
United States of America
APLT
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea
003060
South Korea
003060